Pharma Mar 향후 성장

Future 기준 점검 5/6

Pharma Mar (는) 각각 연간 41% 및 19.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 36.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 27.6% 로 예상됩니다.

핵심 정보

41.0%

이익 성장률

36.76%

EPS 성장률

Biotechs 이익 성장	23.7%
매출 성장률	19.3%
향후 자기자본이익률	27.56%
애널리스트 커버리지	Low
마지막 업데이트	08 Dec 2025

최근 향후 성장 업데이트

Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 02

Recent updates

There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Nov 07

Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 02

Is Pharma Mar (BME:PHM) A Risky Investment?

Oct 29

Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)

Aug 03

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80

Jun 16

Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80

May 23

ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe

Mar 09 Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.

We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit

Mar 06

There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump

Feb 13

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16

이익 및 매출 성장 예측

BME:PHM - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	365	137	88	135	5
12/31/2026	233	59	32	71	5
12/31/2025	211	51	59	62	5
9/30/2025	179	34	16	21	N/A
6/30/2025	189	42	1	9	N/A
3/31/2025	176	20	-18	-10	N/A
12/31/2024	175	26	-9	6	N/A
9/30/2024	167	1	-18	2	N/A
6/30/2024	159	-2	-30	-10	N/A
3/31/2024	162	2	-35	-12	N/A
12/31/2023	158	1	-29	-13	N/A
9/30/2023	168	14	-29	-13	N/A
6/30/2023	175	21	-14	-1	N/A
3/31/2023	177	29	N/A	N/A	N/A
12/31/2022	196	49	29	38	N/A
9/30/2022	235	79	N/A	N/A	N/A
6/30/2022	233	85	41	48	N/A
3/31/2022	232	91	N/A	N/A	N/A
12/31/2021	230	93	18	26	N/A
9/30/2021	188	63	N/A	N/A	N/A
6/30/2021	200	67	19	24	N/A
3/31/2021	222	91	113	117	N/A
12/31/2020	270	137	276	279	N/A
9/30/2020	246	147	264	270	N/A
6/30/2020	214	124	255	259	N/A
3/31/2020	166	72	161	165	N/A
12/31/2019	86	-9	-28	-24	N/A
9/30/2019	136	-27	-24	-23	N/A
6/30/2019	84	-37	N/A	-12	N/A
3/31/2019	154	-24	N/A	-22	N/A
12/31/2018	109	-17	N/A	-17	N/A
9/30/2018	189	-16	N/A	-20	N/A
6/30/2018	128	-20	N/A	-22	N/A
3/31/2018	179	-26	N/A	-19	N/A
12/31/2017	159	-28	N/A	-1	N/A
9/30/2017	182	-22	N/A	4	N/A
6/30/2017	186	-18	N/A	9	N/A
3/31/2017	184	-19	N/A	13	N/A
12/31/2016	181	-24	N/A	-8	N/A
9/30/2016	187	-18	N/A	N/A	N/A
6/30/2016	188	-10	N/A	5	N/A
3/31/2016	190	-7	N/A	N/A	N/A
12/31/2015	194	7	N/A	11	N/A
12/31/2014	175	13	N/A	23	N/A

애널리스트 향후 성장 전망

수입 대 저축률: PHM 의 연간 예상 수익 증가율(41%)이 saving rate(2.4%)보다 높습니다.

수익 vs 시장: PHM 의 연간 수익(41%)이 Spanish 시장(7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: PHM 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: PHM 의 수익(연간 19.3%)이 Spanish 시장(연간 4.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: PHM 의 수익(연간 19.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PHM의 자본 수익률은 3년 후 27.6%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/23 16:30
종가	2025/12/23 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Pharma Mar, S.A.는 12명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Guilherme Sampaio	Banco BPI, S.A.
Patricia Cifuentes	Bestinver Sociedad De Valores, S.A
Keay Nakae	Chardan Capital Markets, LLC

Pharma Mar 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Consensus EPS estimates fall by 17%

Price target increased by 8.9% to €107

Consensus EPS estimates fall by 27%

Consensus revenue estimates increase by 18%, EPS downgraded

Consensus EPS estimates fall by 40%

Recent updates

There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Third quarter 2025 earnings released

Is Pharma Mar (BME:PHM) A Risky Investment?

Pharma Mar, S.A. to Report Q3, 2025 Results on Oct 30, 2025

Consensus EPS estimates fall by 17%

Price target increased by 8.9% to €107

New major risk - Share price stability

Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)

Pharma Mar, S.A. to Report First Half, 2025 Results on Jul 30, 2025

Upcoming dividend of €0.80 per share

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80

Consensus EPS estimates fall by 27%

Pharmamar Announces Positive Results from the Phase 3Imforte Study of Zepzelca®? (Lurbinectedin) in Combination with Atezolizumab

Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80

Investor sentiment improves as stock rises 19%

Dividend increased to €0.80

First quarter 2025 earnings released

Pharma Mar, S.A. to Report Q1, 2025 Results on Apr 24, 2025

Consensus revenue estimates increase by 18%, EPS downgraded

Pharma Mar, S.A., Annual General Meeting, Jun 18, 2025

New major risk - Share price stability

ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe

Consensus EPS estimates fall by 40%

We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit

Price target increased by 7.8% to €83.00

Full year 2024 earnings: Revenues exceed analyst expectations

Consensus EPS estimates increase by 46%

Price target increased by 7.8% to €91.00

There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump

Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025

Consensus EPS estimates increase by 40%

Consensus EPS estimates increase by 1,655%

Consensus EPS estimates increase from loss to €0.017 profit

Consensus EPS estimates have been downgraded.

Price target increased by 10% to €71.33

Third quarter 2024 earnings released

Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024

Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Price target increased by 17% to €60.33

New major risk - Share price stability

Second quarter 2024 earnings released

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024

Consensus EPS estimates increase by 149%

Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Consensus EPS estimates fall by 76%

Dividend of €0.53 announced

Consensus EPS estimates fall by 29%

New major risk - Dividend sustainability

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: €0.06 (vs €2.73 in FY 2022)

Consensus EPS estimates fall by 78%

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Price target decreased by 9.1% to €49.83

Consensus EPS estimates fall by 13%, revenue upgraded

New major risk - Earnings quality

Second quarter 2023 earnings released

Price target decreased by 7.4% to €54.83

Consensus EPS estimates fall by 35%

Price target decreased by 9.7% to €57.17

Consensus EPS estimates fall by 22%

Pharma Mar, S.A., Annual General Meeting, May 31, 2023

Price target decreased by 11% to €61.20

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 23%, revenue upgraded